Abcuro Secures $66 Million in Series D Funding Led by New Leaf Venture Partners

Abcuro Raises $66 Million in Series D Funding

Abcuro, a company based in Newton, Massachusetts, has successfully closed a $66 million Series D funding round. The company focuses on the precision targeting of highly cytotoxic T cells in autoimmune diseases, aiming to provide more effective treatment options for patients.

Key Investors in the Round

The funding round was led by New Leaf Venture Partners. Other participants included abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay, and Rock Springs Capital.

Strategic Use of Funds

While specific plans for the newly raised funds have not been detailed, companies in this space typically use such capital to advance clinical trials, enhance research and development capabilities, and potentially expand their market reach. Abcuro is likely to continue its development efforts to improve therapies for autoimmune diseases.

About Abcuro

Abcuro is making strides in the field of autoimmune disease treatment by focusing on the precision targeting of cytotoxic T cells. This approach aims to deliver targeted therapies that can mitigate the impact of autoimmune disorders, providing hope for improved patient outcomes.